Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for All Participants:~* HIV infected~* HBV infected~* Serum HBV DNA of 100,000 copies/ml or greater~* Positive for serum hepatitis B surface antigen (HBsAg) within 12 weeks prior to study entry~* Agree to use acceptable methods of contraception~* Serum alpha-fetoprotein (AFP) of 50 ng/ml or less within 30 days of study entry. If AFP is greater than 50 ng/ml, the patient must have an imaging study of the liver showing no tumor within 30 days prior to study entry~Inclusion Criteria for Population A:~* Uninterrupted stable HAART regimen at study entry for at least 12 continuous weeks prior to study entry~* HIV viral load of 10,000 copies/ml or less within 12 weeks of study entry~Inclusion Criteria for Population A, Group I:~* Compensated liver disease~* Child-Pugh-Turcotte (CPT) score of less than 7~Exclusion Criteria for Population A, Group I:~* Excess fluid in the space between the membranes lining the abdomen and abdominal organs (ascites)~* Gastrointestinal (variceal) bleeding~* Brain and nervous system damage as a result of liver disease~* Abnormal blood clotting time~Inclusion Criteria for Population A, Group II:~* Decompensated liver disease~* CPT score of 7-12~Inclusion Criteria for Population B:~* Prior HAART regimen~* Never taken TDF as part of HAART regimen~* Serum HBV DNA of 100,000 copies/ml or greater within 12 weeks of study entry~* HIV viral load of greater than 10,000 copies/ml within 12 weeks of study entry~* CPT score less than 13~Exclusion Criteria~* Serious kidney problems within the last 12 months~* Allergic or sensitive to ADV or TDF~* Active hepatitis C virus (HCV) disease or unknown HCV status within 24 weeks of study entry~* Any medical or mental illness that, in the opinion of the investigator, would interfere with the protocol~* Past or current alcohol or drug abuse that would affect the protocol~* Malignancy that, in the opinion of the investigator, would make the patient unsuitable for the study~* Certain anti-HBV drugs within 90 days of study entry or expected use of these agents during the course of the study~* Drugs that may damage the kidneys within 8 weeks prior to study screening or expected use of these agents during the course of the study~* Systemic corticosteroids within 90 days of study entry~* Current use of drugs containing pivalic acid~* Certain investigational anti-HIV agents~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).